The FDA Expands Collaboration With CN Bio to Investigate Lung-on-a-chip Model for Inhaled Drug Evaluation Applications
Follows success of initial project demonstrating the advanced performance of the Company s liver-on-a-chip platform
CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the U.S. Food and Drug Administration (FDA) has extended their research collaboration, for a further three years. The scope of the research carried out with the FDA s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio s lung-on-a-chip using the PhysioMimix MPS platform, to appraise the system s use for the evaluation of inhaled drug products and assessing additional applications for CN Bio s liver model.
Industry News: CN Bio FDA collaboration expanded to investigate lung-on-a-chip model for inhaled drug evaluation applications
Extension aims to evaluate CN Bio’s PhysioMimix lung-on-a-chip platform in addition to deepening existing research collaboration for liver studies
05 May 2021
CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, has announced the U.S. Food and Drug Administration (FDA) has extended their research collaboration, for a further three years. The scope of the research carried out with the FDA’s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio’s lung-on-a-chip using the PhysioMimix™ MPS platform, to appraise the system’s use for the evaluation of inhaled drug products and assessing additional applications for CN Bio’s liver model.
Product News: CN Bio’s PhysioMimix technology receives FDA recognition
13 Jan 2021
CN Bio, one of the leading developers of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, has announced the publication of co-authored research with the U.S. Food and Drug Administration (FDA)1. The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using CN Bio’s proprietary PhysioMimix™ system is appropriate for use in drug safety and metabolism applications, evidencing its enhanced performance versus standard techniques. The publication substantiates the Company’s position as a leader in the field with reliable and robust cutting-edge technology, ready for widespread adoption across the pharmaceutical industry.